| Literature DB >> 34222365 |
Ya-Lin Zhao1, Ping Yuan2, Qin-Hua Zhao2, Su-Gang Gong2, Rui Zhang2, Jing He2, Ci-Jun Luo2, Hong-Ling Qiu2, Jin-Ming Liu2, Lan Wang2, Rong Jiang2.
Abstract
Background: Patients with chronic thromboembolic pulmonary hypertension (CTEPH) still experience reduced exercise capacity despite pulmonary endarterectomy (PEA). Exercise training improves the exercise capacity and quality of life (QoL) in patients with PH, but data on the effects of exercise training on these patients are scarce. The aim of this meta-analysis and systematic review was to evaluate the effectiveness and safety of exercise training in CTEPH after PEA.Entities:
Keywords: cardiorespiratory fitness; exercise intolerance; exercise training; pulmonary endarterectomy; pulmonary hypertension
Year: 2021 PMID: 34222365 PMCID: PMC8245692 DOI: 10.3389/fcvm.2021.664984
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Figure 1Flow diagram.
Characteristics of all included studies.
| Nagel et al. ( | • In the Rehabilitation Clinic (first 3 weeks): | 3 weeks; 15 weeks. | 6 MWD; CPET variables; stress Doppler echocardiography; HR; blood pressure; Borg dyspnoea index; WHO-FC; SF-36; NT-proBNP; gas exchange | 6 MWD↑; SF-36 scores for physical functioning and vitality↑; peak VO2↑; peak VO2/kg↑; workload↑; an increase of maximal HR↑; NT-proBNP↓; WHO-FC(-). | |
| Inagaki et al. ( | In-hospital each week (40–60 min) and home-based programme, including: | 12 weeks | Echocardiography; BNP; exercise capacity; dyspnoea severity and the functional status; pulmonary function; peripheral muscle force; physical activity. | 6 MWD↑; TDI scores↑; QF↑; Ex↑; SGRQ scores↑; No change in MRC scores, BDI scores, HRR1, and WHO-FC. | |
| La Rovere et al. ( | Group 1 = 84, Age: 60.4 ± 13.8 years, Female: 6; Group 2 = 26, Age: 57.9 ± 13.1 years, Female: 31. | Daily sessions of: | 3 months | 6 MWD; pulse oximetric oxygen saturation, lung function tests; arterial blood gases; hemodynamics. | PAP↓; TPG↓; RVEF↑; PVR↓; PaO2↑; pH↓; No changes in RAP, PCWP, CO, CI, SVR, PVR,TPR, PaCO2, FEV1,% predicted, FVC, % predicted, and FEV1/FVC, % predicted |
| Nagel et al. ( | • In the rehabilitation clinic (first 3 weeks): | 3 weeks; 19 weeks. | WHO-FC; 6 MWD; BDI scores; echocardiography; lung function; blood gas; SF-36; CPET with stress echocardiography. | 6 MWD↑; SF-36 scores for physical functioning and vitality↑; peak VO2↑; peak VO2/kg↑; workload↑; NT-proBNP↓; RA area↓; RV area↓; sPAP↓; TAPSE↑; left ventricular eccentricity index↓; tissue Doppler imaging s RV free wall↑; oxygen pulse↑; EqCO2↓; BDI↓; HR↓; peak HR↓; O2 at AT↑. |
VE, ventilation; VO.
COMPARED integrated two groups with 3-month vs. after surgery (before rehabilitation).
Figure 2Forest plots for the 6-min walking distance. 6MWD, six-minute walking distance.
Changes in cardiopulmonary exercise testing after exercise training in CTEPH patients with PEA.
| Peak VO2/kg | 3.15 (0.82, 5.48) | 53.78 | 0.008 |
| after 3 weeks | 1.99 (1.48, 2.50) | 16.26 | |
| after 12/15 weeks | 4.37 (3.48, 5.26) | 16.17 | |
| Peak VO2 | 292.69 (24.62, 560.75) | 3.45 | 0.032 |
| after 3 weeks | 158.50 (122.50,194.50) | 1.08 | |
| after 12/15 weeks | 432.09 (349.76, 514.42) | 0.22 | |
| VO2 at AT | 136.32 (−66.78, 339.41) | 1.11 | 0.188 |
| after 3 weeks | 37.07 (−34.72, 108.86) | 0.29 | |
| after 12/15 weeks | 244.50 (133.71, 355.29) | 0.12 | |
| Workload max | 26.69 (9.41, 43.98) | 41.65 | 0.002 |
| after 3 weeks | 18.18 (13.05, 23.31) | 12.69 | |
| after 12/15 weeks | 35.83 (27.53, 44.13) | 9.33 | |
| O2 pulse | 1.55 (0.40, 2.70) | 33.09 | 0.008 |
| after 3 weeks | 0.98 (0.48, 1.48) | 11.41 | |
| after 12/15 weeks | 2.15 (1.50, 2.80) | 10.97 | |
| HR rest | −2.70 (−7.75, 2.35) | 10.8 | 0.295 |
| after 3 weeks | −0.36 (−3.16, 2.44) | 4.09 | |
| after 12/15 weeks | −5.54 (−9.76, −1.32) | 2.21 | |
| HR max | 10.41 (−0.66, 21.48) | 4.66 | 0.065 |
| after 3 weeks | 4.95 (−0.20, 10.10) | 1.58 | |
| after12/15 weeks | 16.25 (9.69, 22.81) | 1.03 | |
| SaO2 rest | 0.55 (0.02, 1.08) | 31.10 | 0.043 |
| after 3 weeks | 0.39 (−0.24, 1.02) | 11.02 | |
| after 12/15 weeks | 0.94 (−0.05, 1.93) | 9.72 | |
| SaO2 max | 1.18 (−0.18, 2.54) | 20.35 | 0.088 |
| after 3 weeks | 0.57 (−1.31, 2.45) | 6.41 | |
| after 12/15weeks | 1.85 (−0.11, 3.81) | 6.16 | |
SaO.
Forest plots of pulmonary hemodynamic measurements.
| RAP, mmHg | −0.04 (−2.26, 2.18) | 0.97 | −0.14 (−0.94, 0.66) | 0.74 |
| mPAP, mmHg | −18.10 (−29.35, −6.84) | 0.002 | −0.18 (−5.60, 5.25) | 0.95 |
| PCWP, mmHg | 1.46 (0.04, 2.87) | 0.04 | −0.24 (−1.10, 0.63) | 0.59 |
| TPG, mmHg | −20.01 (−29.98, −10.03) | <0.0001 | 0.34 (−4.36, 5.05) | 0.89 |
| CO, L/min | 0.92 (0.59, 1.25) | <0.00001 | 0.20 (−0.10, 0.50) | 0.19 |
| CI, L/min/m2 | 0.49 (0.20, 0.77) | 0.0009 | 0.10 (−0.04, 0.24) | 0.17 |
| RVEF, % | 9.12 (6.31, 11.94) | <0.00001 | 3.53 (1.11, 5.95) | 0.004 |
| SVR, dyn·s·cm−5 | −548.87 (−687.29, −410.44) | <0.00001 | 92.20 (−15.24, 199.63) | 0.09 |
| PVR, dyn·s·cm−5 | −538.61 (−744.64, −332.59) | <0.00001 | 1.19 (−78.37, 80.75) | 0.98 |
| TPR, dyn·s·cm−5 | −532.00 (−773.86, −290.13) | <0.0001 | −10.72 (−103.32, 81.87) | 0.82 |
RAP, right atrial pressure; mPAP, mean pulmonary arterial pressure; PCWP, pulmonary capillary wedge pressure; TPG, transpulmonary gradient; CO, cardiac output; CI, cardiac index; RVEF, right ventricular ejection fraction; SVR, systemic vascular resistance; PVR, pulmonary vascular resistance; TPR, transpulmonary resistance; PEA, pulmonary endarterectomy; MD, mean difference.
The effect of exercise training on NT-proBNP, arterial blood gases, echocardiography, and pulmonary function test in patients with CTEPH after PEA.
| −524.79 (−705.16, −344.42) | 0 | <0.0001 | |
| Changes after 3 weeks | −482.30 (−698.90, −269.70) | ||
| Changes after 19 weeks | −622.21 (−955.09, −289.33) | ||
| PaO2, mmHg | 9.30 (6.04, 12.55) | 0 | <0.00001 |
| PaCO2, mmHg | 1.72 (0.54, 2.89) | 48 | 0.004 |
| pH | 0.01 (0, 0.02) | 0 | 0.04 |
| PaO2, mmHg | 4.67 (1.01, 8.33) | 0 | 0.01 |
| PaCO2, mmHg | 0.90 (−0.28, 2.08) | 0 | 0.13 |
| pH | −0.03 (−0.04, −0.02) | 0 | <0.00001 |
| After 3 weeks | −1.20 (−3.14, 0.74) | 0 | 0.225 |
| sPAP rest | −1.29 (−3.55, 0.97) | ||
| sPAP max | −0.95 (−4.74, 2.84) | ||
| After 19 weeks | 7.42 (3.87, 10.97) | 0 | <0.0001 |
| sPAP rest | 6.37 (2.23, 10.51) | ||
| sPAP max | 10.35 (3.44, 17.26) | ||
| FVC % predicted | 4.10 (−0.63, 8.83) | 0 | 0.09 |
| FEV1 % predicted | 3.30 (−2.72, 9.32) | 0 | 0.28 |
| FEV1/FVC % predicted | 2.70 (−1.13, 6.53) | 0 | 0.17 |
NT-proBNP, N-terminal pro-brain-type natriuretic peptide; PEA, pulmonary endarterectomy; PaO.
Figure 3Forest plots for the quality of life. IV, inverse variance.
Adverse effects reported in the included studies.
| Nagel et al. ( | 45 | Syncope in one patient; Herpes zoster infection in one patient. |
| Shamseer et al. ( | 8 | Low blood pressure and tachycardia in one patient |
| La Rovere et al. ( | 110 | None |
| Nagel et al. ( | 45 | None |